Bio-Rad Laboratories (BIO)

Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Strong Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. BIO has maintained this ranking for the last month.

Bio Rad Laboratories Inc (NYSE:BIO) is ranked as a Strong Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. BIO has recently seen its Portfolio Grader rating upgraded from a Buy to a Strong Buy.

With a $7.6 billion market value, Bio Rad Laboratories Inc (NYSE:BIO) ranks in the upper half of its industry group, Life Sciences Tools & Services, and in the top quarter of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 1 among the 32 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 10 among the 781 companies in the sector, and number 69 in the nearly 5,000 company Portfolio Grader universe.

Bio Rad Laboratories Inc (NYSE:BIO) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part of the 782 company GICS Health Care sector. BIO has a market value of $7.7 billion which is in the top 25% of its industry group. The stock's current Portfolio Grader score places it 1 among the 33 companies in this industry group, putting it in the top decile; among the sector leaders with a ranking of 10 among the 782 companies in the sector, and number 69 in the nearly 5,000 company Portfolio Grader universe.

Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Strong Buy using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. BIO has been upgraded from a Buy to a Strong Buy in the last week.

Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for 2 months.

Bio Rad Laboratories Inc (NYSE:BIO) ranks in the top half of its industry group, Life Sciences Tools & Services, and in the top 25% of its sector group, Health Care, with a market value of $6.6 billion. From an investment attractiveness viewpoint, BIO is ranked in the top quartile of the sector with a ranking of 99 among the 782 companies in the sector; the ranking for BIO by Portfolio Grader places it 9 among the 33 companies in this industry group, putting it in the second quartile and number 756 in the 5000 company Portfolio Grader company universe.

The current recommendation of Buy for Bio Rad Laboratories Inc (NYSE:BIO) has been derived by using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methods. This represents no change from the previous week and is the same ranking BIO has had from Portfolio Grader for 2 months.

Bio Rad Laboratories Inc (NYSE:BIO) is ranked as a Buy using Louis Navellier's system for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BIO has had from Portfolio Grader for the last month.

Bio Rad Laboratories Inc (NYSE:BIO) is ranked as a Buy using Louis Navellier's system for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BIO has had from Portfolio Grader for the last month.